Tajunisah Iqbal, Tan Shao Sze, Effendi-Tenang Irina, Samsudin Amir, Ling Kiet-Phang, Tan Wee Yong, Ramasamy Sunder, Fong Kenneth Choong Sian
University of Malaya Eye Research Centre (UMERC), Department of Ophthalmology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Ophthalmology, Oasis Eye Specialists, Johor Bahru, Malaysia.
Front Cell Infect Microbiol. 2023 Sep 15;13:1243055. doi: 10.3389/fcimb.2023.1243055. eCollection 2023.
We report the ocular findings that patients experienced after receiving the coronavirus disease 2019 (COVID-19) vaccination in three different eye centers in Malaysia.
A total of four cases were reported. Three patients received the Pfizer-BioNTech vaccine, while the other received the Oxford AstraZeneca type. Ocular symptoms occurred after the first vaccine dose in two patients and after the second vaccine dose in the other two. Three out of four patients required active treatment for their vision complications postvaccination. The first patient had acute-onset retinal pigment epitheliitis within 3 h of vaccination and was treated conservatively. The second patient developed unilateral choroidal neovascularization 3 days after vaccination and required intravitreal antivascular endothelial growth factor injection. The third patient presented with bilateral acute multifocal placoid pigment epitheliopathy a week after vaccination and responded to intravenous methylprednisolone. The fourth patient presented with herpes zoster infection and unilateral anterior nongranulomatous uveitis 2 weeks after vaccination and was treated with oral acyclovir and topical corticosteroids. All patients reported some amount of visual recovery.
Visual symptoms and various ocular adverse events can occur following COVID-19 vaccination, which warrants further investigation and urgent intervention if necessary. We would suggest patients receiving the COVID-19 vaccination be aware of possible ocular complications and report any symptoms, regardless of severity.
我们报告了马来西亚三个不同眼科中心的患者在接种2019冠状病毒病（COVID-19）疫苗后出现的眼部情况。
共报告了4例病例。3名患者接种了辉瑞-生物科技疫苗，另1名接种了牛津阿斯利康疫苗。2名患者在接种第一剂疫苗后出现眼部症状，另外2名在接种第二剂疫苗后出现症状。4名患者中有3名在接种疫苗后因视力并发症需要积极治疗。第一名患者在接种疫苗后3小时内急性发作视网膜色素上皮炎，接受了保守治疗。第二名患者在接种疫苗后3天出现单侧脉络膜新生血管，需要玻璃体内注射抗血管内皮生长因子。第三名患者在接种疫苗一周后出现双侧急性多灶性扁平状色素上皮病变，对静脉注射甲泼尼龙有反应。第四名患者在接种疫苗2周后出现带状疱疹感染和单侧前部非肉芽肿性葡萄膜炎，接受了口服阿昔洛韦和局部使用皮质类固醇治疗。所有患者均报告视力有一定程度的恢复。
COVID-19疫苗接种后可能出现视觉症状和各种眼部不良事件，如有必要，这需要进一步调查和紧急干预。我们建议接种COVID-19疫苗的患者了解可能的眼部并发症，并报告任何症状，无论严重程度如何。
